Universal Screening to Assess Chlamydia Prevalence and Risk Among Older Women Attending Family Planning Clinics in Wisconsin Roberta (Bobbie) McDonald.

Slides:



Advertisements
Similar presentations
Wisconsin State Report RVIPP Meeting March 4-5, 2009 Highlight Updates Screening Projects: Prevalence Evaluation Update; Expanded GC Screening in Milwaukee.
Advertisements

WI State Report RVIPP, Indianapolis, IN June 9-10, 2010.
Donald T. Simeon Caribbean Health Research Council
Bugs, Drugs, Dollars and Tests Making the Most of Scarce Resources for Chlamydia and Gonorrhea Screening and Treatment.
How to Measure the Effectiveness of the IPP (and all the CT Screening being done)? **Reduce Infertility** Ultimate Goal Reduce PID Reduce Chlamydia Prevalence.
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
Revision of Region II IPP Screening Criteria May 16, 2007 Region II IPP Advisory Committee Meeting Cicatelli Associates Inc. New York City.
Epidemiology of Chlamydia in the United States Debra J. Mosure, Ph.D. Division of STD Prevention Centers for Disease Control and Prevention March 8, 2004.
Repeat Chlamydial Infections in Region III Family Planning Clinics: Implications for Screening Programs Pamela G. Nathanson, Family Planning Council, Inc.
CVD Risk Reduction Group Retention Draft Guidelines May 2005.
Distribution of Trichomonas vaginalis Among Women at High Risk for HIV Infection Barbara Van Der Pol, James Williams, Jacquelyn Murphy and the Project.
Evaluation of Gonorrhea Screening in Family Planning Settings: California 2000 CK Kent, M Brammeier, G Bolan, N Casas, M Funabiku, P Blackburn Region IX.
Using Test Kit Allotments to Reduce Chlamydia Screening in Low Risk Females for Re-allocation to Higher Risk Populations and Higher Yield Venues Rabins.
Appropriate CT/GC Screening & Factors to Consider Becky McCoy MSN, RN, CEN STD Nurse Consultant.
Analysis of Chlamydia Re-testing Rates Massachusetts Family Planning Update.
Reaching Out to Providers Summary of Region II IPP Tools.
Program Collaboration and Service Integration: An NCHHSTP Green paper Kevin Fenton, M.D., Ph.D., F.F.P.H. Director National Center for HIV/AIDS, Viral.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2003 Division of STD Prevention.
Re-Screening of CT Positive Clients in Region X IPP, Goldenkranz S., 1 Fine D. 1 1 Center for Health Training 2010 CDC STD Prevention Meeting,
Region I IPP Clinic Staff and Provider Assessment Kim Watson, Jennifer Kawatu.
STDs among Men who Have Sex with Men (MSM), San Francisco 2007—2010 STD Prevention and Control Services San Francisco Department of Public Health.
STD Surveillance Network (SSuN) Cycle 2 Objectives Lori Newman & Kristen Mahle SSuN Principal Collaborators Meeting Atlanta, GA December 2, 2008.
US Virgin Islands IPP: Use of Limited Resources Taetia Phillips-Dorsett, MS Territorial Director, USVI DOH STD/HIV/TB Program Region II IPP Advisory Meeting.
Chlamydial Infections in the U.S. Steven J Shapiro CCID/NCSHHSTP/DSTDP/PTB Region I Infertility Prevention Project Wells Beach, Maine June 2, 2009 Disclaimer:
“The Effect of Patient Complexity on Treatment Outcomes for Patients Enrolled in an Integrated Depression Treatment Program- a Pilot Study” Ryan Miller,
Unit 3: Universal Case Reporting and Sentinel Surveillance for STIs
State and Local STD Prevention Programs Prepared by Jim Lee, Senior Public Health Advisor, Texas Department of State Health Services and Melinda Salmon,
EFFICACY OF A STAGE-BASED BEHAVIORAL INTERVENTION TO PROMOTE STI SCREENING IN YOUNG WOMEN: A RANDOMIZED CONTROLLED TRIAL Chacko MR, Wiemann CM, Kozinetz.
Region II IPP Data & Infrastructure Performance Measures Kelly Opdyke, MPH Region II IPP Advisory Committee Mtg May 16-17, 2007 Cicatelli Associates Inc.
IPP Measures of Effectiveness Utilization of Data to Evaluate and Inform Project Activities December 12, 2007 Kelly Morrison Opdyke, MPH Region II Infertility.
Infrastructure Update Jennifer Kawatu Kim Watson Andee Krasner
Targeting Chlamydia Screening Resources Region II IPP Advisory Meeting May 31, 2006 Kelly Opdyke, MPH Cicatelli Associates Inc.
BASELINE ASSESSMENT OF CHLAMYDIA REINFECTION IN REGION VIII FAMILY PLANNING CLINICS FOR Hamby, Y, JSI Research & Training Institute Donovan,
Reaching Adolescents Michigan’s Infertility Prevention Screening Project.
STD’s in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2001 Division of STD Prevention.
Efficacy of a “One-Shot” Computerized, Individualized Intervention to Increase Condom Use and Decrease STDs among Clinic Patients with Main Partners Diane.
Region I IPP Data Presentation Advisory Board Meeting June 2008 Wells, ME.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2004 Division of STD Prevention.
INTRODUCTION TO SYNDROMIC MANAGEMENT OF STIs
NAAT identified chlamydial infections: Enhanced sensitivity, reduced transmissibility? Presenter: Maria Villarroel, MA Authors: Maria A. Villarroel, MA.
TB in Yorkshire and the Humber Dr Simon Padfield 14 th Sept 2007.
Region II Infertility Prevention Project Advisory Committee May 16-17, 2007 New York, New York Steven J. Shapiro Infertility Prevention Project Coordinator.
IPP Infrastructure Measures of Effectiveness: Preliminary Data and Next Steps Kelly Morrison Opdyke, MPH Region II Infertility Prevention Project Cicatelli.
The Dublin Well Woman Centre and The National Virus Reference Laboratory  Approved by ICGP Ethics Committee.
Self-taken extragenital samples compared with clinician-taken extragenital samples for the diagnosis of gonorrhoea and chlamydia in women and MSM Janet.
Developing and Improving a Fast Track Services Program in Chicago STD Clinics William Wong, MD Division of STD/HIV/AIDS Chicago Department of Public Health.
Mayuri Dasari M.D. Cook County Loyola Provident
Risk Behaviour, Health Care Access and Prevalence of infection with Chlamydia trachomatis and Neisseria gonorrhoea in a population based sample of.
J. Mossong1, N. Majéry2, C. Mardaga3 , M. Muller4, F. Schneider1
1University of Kentucky, Lexington, Kentucky
Gonorrhoea & PID PHCP 402 By K S Labaran.
Xth International Conference on AIDS and STD in Africa, December 1997
It's not what you know, but who you know: Risk factors for re-infection in the Philadelphia High School STD Screening Program Jennifer Beck, MPH APHA.
Emilia H. Koumans, Fujie Xu, Maya Sternberg, Lauri E. Markowitz
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
Cost of Screening Outside of IPP Chlamydia Screening Guidelines
A study of high risk African American women, 15 to 21 years of age
Blinded Hepatitis C Antibody Serosurvey among clients using the Wisconsin HIV Counseling, Testing, and Referral Program Angela Russell, MS John Pfister,
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
Martin Goldberg1, Daniel R. Newman2, TA Peterman2,
Mark Lobato, MD Division of TB Elimination
Natural Family Planning (NFP) Research Study
Prevalence of Rectal Chlamydia and Gonorrhea Before and After Implementation of Routine Rectal Screening Ellen T. Rudy Sexually Transmitted Disease Program.
The Relationship between Recent Alcohol Use and Sexual Behaviors/STDs: Gender Differences among STD Clinic Patients Heidi E. Hutton PhD, Mary E. McCaul.
Infertility Prevention Project Coordinator CDC/CCID/NCHHSTP/DSTDP/PTB
Family Planning & STDP Brainstorming
Region I IPP Data Update Region I IPP Advisory Board Meeting
2008 National STD Prevention Conference Chicago, Illinois
Finding Sex Partners On-Line: What’s the Risk for STI
Gonorrhea Screening: What Do the Data Tell Us?
Presentation transcript:

Universal Screening to Assess Chlamydia Prevalence and Risk Among Older Women Attending Family Planning Clinics in Wisconsin Roberta (Bobbie) McDonald Wisconsin State Laboratory of Hygiene, Madison, WI Region V Infertility Prevention Project STD Prevention Conference, March 12, 2008 Chicago, IL bobbie@mail.SLH.wisc.edu

WI Chlamydia Program History CT Testing in WI Family Planning clinics since the 1980’s (culture, then EIA/DFA) Challenges faced in implementing a cohesive screening program Limited resources available (technology, $) Little data, no formal recommendations Diverse population across WI; urban vs. rural Supporting factors included: Good relationships between providers, lab & program Visionary early leadership

History of Universal Screening Studies in WI First ‘Universal Screening’ studies in FP Established evidence-based screening criteria Positivity justified continued screening in FP Universal screening has been revisited in 5-7 year intervals to address: Changes in test technology and costs Epidemiology, local data, demographics National recommendations (age-based)

Universal Screening Study Model Periods of ‘universal’ testing and expanded data collection in a representative subset of family planning clinics Test results matched with patient and clinician questionnaire data (behavioral, demographic and clinical risk factors) Often used as an opportunity to examine other program issues (assay performance comparisons, specimen validation, etc.) Use locally-derived data to establish/ evaluate selective screening criteria

History of Universal Screening Studies in WI Universal screening studies in WI FP: 1985 (rural, CT-DFA, GC culture) 1986 (urban, GC & CT culture, EIA & DFA) 1990 (GC culture, CT EIA/DFA) 1996-97 (CT-EIA, LCR & PCR) 2001-02 (SDA, males & females, CT and GC) Data analysis in these studies led to our ‘risk-first’ approach In all studies, age was examined as a risk criterion; added as SSC selectively in 2002

2001 Universal Screening Data 8,108 female patients (10 clinics, 7 mos.) 6,572 participants (81%) w/ complete data 4908 (74.7%) age 25 and under 7.7% CT positive overall 87.5% meet SSC, 8.2% CT positive 12.5% of tests outside SSC, 4.4% CT positive 1664 (25.3%) age 26 and over 2.7% CT positive overall 86.5% meet SSC, 2.8% positive 13.5% of tests outside SSC, 1.8% CT positive

2001 Universal Screening Analysis Order is by decreasing risk ratio of individual criteria, and by increasing sensitivity

Milwaukee vs. Non-Milwaukee   Milwaukee Non-Milwaukee Cumulative Selective Patients Meeting Criteria Chlamydia Positive Sensitivity Screening Criteria* # % (% of All +) 1 STD Contact 106 3.9% 19 17.9% 8.3% 112 3.0% 22 19.6% 11.6% 2 Criterion 1 + Symptoms of STD 1,105 40.8% 137 12.4% 59.8% 1,196 31.5% 101 8.4% 53.2% 3 Criteria 2 + Partner Risk 1,575 58.2% 176 11.2% 76.9% 2,011 53.0% 142 7.1% 74.7% 4 Criteria 3 + History of STD 1,780 65.8% 189 10.6% 82.5% 2,193 57.8% 149 6.8% 78.4% 5 Criteria 4 + Age <19 2,009 74.2% 202 10.1% 88.2% 2,610 68.8% 166 6.4% 87.4% 6 Criteria 5 + Age <23 2,251 83.2% 216 9.6% 94.3% 3,133 82.6% 177 5.6% 93.2% 7 Criteria 6 + Age <26 2,406 88.9% 221 9.2% 96.5% 3,399 89.6% 183 5.4% 96.3% 8 Universal Screening 2,707 100% 229 8.5% 3,795 190 5.0%

“Drawing the Line” for SSC Balance positivity, recommendations, risk factors, and various cost measures with the bottom line program budget Consider limitations of study (sample size, participation rate, urban bias State “politics” may also come into play! SSC must be simple enough to use, and accurate enough that it will be used, while effectively targeting program funds Translating universal screening study data into meaningful SSC is complex; never as simple as “test where positivity is over 3%”

Current SSC in WI FP (2002) SEX PARTNER RISK: All within past 90 days Patient had more than one partner Patient had a partner who had more than one partner Patient had a new partner CONTACT: within past 90 days Partner w/ symptoms or diagnosis of CT, GC, NGU, epididymitis, or other STD SYMPTOMATIC Current diagnosis of (or evaluation for) gonorrhea Current diagnosis of or symptoms of PID Cervicitis - mucopurulent discharge or friable cervix Cervical erythema greater than 50% Purulent vaginal discharge HISTORY of STD (note: NOT “Test of Cure”) Confirmed or self-reported CT infection in past 5 years OTHER Protocol testing: Prior to an IUD insertion Pregnancy - prenatal visit SPECIAL AGE CRITERIA Patients not meeting above criteria, but under a specified age may be tested using contract funds in selected clinics. (<19 semi-urban, <23 Milwaukee)

Universal Screening Studies: Impact on Routine CHLAMYDIA (CT) *See complete definitions on reverse of last page* Females  Sex Partner Risk  Contact  Symptomatic  History of STD (NOT “Test of Cure”)  Protocol (pre-IUD) Testing  Prenatal For AUTHORIZED clinics only:  Special Age Criteria Routine testing data re SSC is gathered on the lab form Contract (IPP) funds available only for tests meeting SSC Age criteria is assigned to each clinic based on data Patients tested outside of SSC are selected by clinician for various reasons

Universal vs. Routine Screening 2001 Universal Screening Study Females 2001 Universal Screening Study Females Age distribution quite similar Reduction in tests over age 25 in 2006 compared to universal (20% of tests vs. 25%) Alternate funding sources for CT testing play a role Age 2006 Routine Screening, Females, by Age 2006 Routine Screening, Females, by Age Age

2006 Routine Testing Data 39,107 female patients (~70 clinics) 31,110 (79.6%) age 25 and under 7.9% CT positive overall 85.8% meet SSC, 8.6% CT positive 14.2% of tests outside SSC, 4.3% CT positive 7997 (20.4%) age 26 and over 3.3% CT positive overall 84.6% meet SSC, 3.6% positive 15.4% of tests outside SSC, 1.9% CT positive

2006 Routine Testing by Age

2006 Routine Screening, Age >25

In general, positivity on SSC is about double the off-SSC rate 2006 CT Positivity by Location, Age In general, positivity on SSC is about double the off-SSC rate CT positivity in Milwaukee has always been strikingly higher than the rest of WI Off-SSC CT rates are uniformly low in women over 25 across all of WI! 2006 Positivity by Location, Age, SSC

2008 Universal Screening Study Current Critical Challenges Always needing to do more with less! Impact of FP MA waiver (free testing w/o requirement of meeting SSC) Convince clinicians not to test low-risk older women when there is funding they can access? Increased emphasis on reducing screening in older women (>25? >30?) Reducing low-yield off-SSC testing in all age groups

2008 Universal Screening Goals Increase participation towards “Universal” Clinic-based (NP) Study Coordinator Better training for clinic staff, more follow-up Streamline clinic procedures Improve questionnaire, simplify questions Clinicians provided input into potential new criteria questions Assess specific reasons for off-SSC testing…

“Clinician Impression” Questions Does patient meet current screening criteria?  Yes  No If NO, would you be inclined to test patient outside criteria?  Yes  No If yes, Why? (mark any/all that apply) risks outside the 3-month timeframe reliability of history information provided other reason (specify)______________________________________________ _________________________________________________________ Rate your impression of patient’s overall STD risk from 1 (very low) to 5 (very high): 1 2 3 4 5 Rate your impression of patient’s overall health from 1 (very good) to 5 (very poor):

Summary: CT Screening in WI Women > 25 Universal screening studies can provide data needed to support use of SSC WI’s locally-derived SSC identifies women over age 25 at increased risk of CT infection in WI FP Women over 25 without risk criteria are a small portion of CT tests, with low positivity (=/< 2%), even in high-prevalence areas

Lessons from The WI Experience Using local data to determine SSC may require different criteria for different areas More complex for the program, more effective Each clinic has only one set of SSC to follow Financial incentives can help compliance Alternate sources of funding can complicate SSC use and the ability to monitor Provider behavior can be changed, slowly